Efficacy of Everolimus and Fulvestrant in Resistant Metastatic Breast Cancer: Experience from Uzbekistan

Background: Everolimus, an mTOR inhibitor, is a key component in the treatment of various malignancies, including breast cancer (BC), renal cell carcinoma, and other oncological diseases. In Uzbekistan, the experience with this drug in oncology remains limited, particularly in the treatment of metastatic breast cancer (MBC). According to NCCN guidelines, everolimus is recommended for use in the second-line and subsequent lines of therapy for hormone receptor-positive (HR+)/HER2-negative recurrent metastatic BC (stage IV, M1), particularly in cases of resistance to CDK4/6 inhibitors.